1研究計畫中英文摘要
(1) 中文摘要：
醫用直線加速器所產生之輻射包括光子或電子，當光子能量超過 10 MeV 以上時，會
提高其發生光核反應的機率，而可能產生出高 LET 的光中子輻射；同樣的醫用直線加速
器所產生之高能量電子亦會產生高能量之制動輻射(X 光)，再間接產生出光中子。這些光
中子輻射所造成之輻射效應能否被忽略乃有待進一步評估與驗證。在輻射劑量的評估上，
由於輻射在細胞中靶分子內的微觀劑量乃呈現極大之分佈，對高 LET 的輻射而言，多呈
一極端不對稱，其平均吸收劑量與最多可能值之間的差異很大。因此本研究計畫以國際上
常使用之組織等效比例計數器作為微劑量評估儀器，逐步評估分析醫用直線加速器之不同
能量光子進行治療的微劑量分佈。結果將提供予臨床直線加速器治療部門之劑量參考。
關鍵詞：直線加速器、微劑量、相對生物效應
(2) Abstract：
Photon and electron beams are the main radiations produced by the linear accelerator
(Linac). As the photon energy is beyond 10 MeV, probabilities of photonuclear reactions are
increased; secondary particles such as high LET photoneutron radiations are then following
emitted. Besides, electrons are also induced bremmstrahlung X ray, and the photoneutron shown.
It’s necessary to assess and make further verification to the effects of these photoneutrons. In
dosimetry, due to the distinct distributions of doses in micro-cell targets, the distributions
present extremely asymmetric for high LET radiations. The difference between average
absorbed dose and most probable dose is un-ignored. In this work, the microdosimetry
equipment: tissue equivalent proportional counters were applied to analyze and assess the
microdosimetric distributions in different photon energies of Linac radiotherapy, step by step.
Results of this project can be the reference as the index of the quality of the therapy unit.
Keywords: Linear accelerator, microdosimetry, RBE
3報告內容
一、前言
醫用直線加速器所產生之輻射包括光子或電子，當光子能量超過 10MeV 以上時，會
提高其發生光核反應的機率，而可能產生出高 LET 的光中子輻射；同樣的醫用直線加速器
所產生之高能量電子亦會產生高能量之制動輻射(X 光)，再間接產生出光中子。這些光中
子輻射所造成之劑量，既不在現有之電腦治療計畫的劑量評估考量內，所造成之額外的傷
害效應亦未被考量，中子輻射效應能否被忽略乃有待進一步評估與驗證。在輻射劑量的評
估上，由於輻射在細胞中靶分子內的微觀劑量乃呈現極大之分佈，對高 LET 的輻射而言，
多呈一極端不對稱，其吸收劑量與最多可能值之間的差異很大。因此本研究計畫以微劑量
學方法評估醫用直線加速器所產生之不同 LET 輻射，其殺死癌細胞的傷害效應，並以有效
相對生物效應作為參考指標。本研究計畫擬以三年的時間，以國際上常使用之組織等效比
例計數器作為微劑量評估儀器，分析評估醫用直線加速器進行治療之微劑量分佈。本期計
畫執行期限自 96 年 8 月 1 日，至 97 年 11 月 30 日止，為整體研究規劃三年時間之第一年，
第二期計畫執行期限自 97 年 8 月 1 日，至 99 年 7 月 31 日止，亦已獲得補助，現正按規劃
時程進行中。
二、材料與方法
2.1 微劑量學參數
微劑量學在探討微小體積之組織或細胞中各種輻射的能量沉積情形，以線能(lineal
energy, y)與比能(specific energy, z)分別表示輻射的品質與劑量。線能 y 之定義為單次輻射事
件授與一微觀體積之沉積能量ε與該微觀體積的平均弦長(mean chord length, l )之比，即：
l
ε
y ........................................................................................................ (公式 1)
線能 y 為機率量，其單位為 keV/µm，與非機率量之直線能量轉移 LET 相比，由於 LET 僅
考慮輻射徑跡附近的局部能量轉移，亦不考慮游離出較高能量 δ射線之影響，因此無法藉
以得知輻射在靶物質中之確實能量沉積；由於影響生物效應之靶分子的尺寸通常在 10nm
至 10m 之間，在此長度範疇下，統計的變化將使 LET 定義之非機率量失去原先的意義，
若以 LET 的觀念去解釋相關的生物效能 (biological effectiveness) 將受限制。而線能則個別
獨立的能量沉積事件(包括δ射線)之能量轉移的能量沉積結果，也因此其每次之輻射能量沉
積結果均可能不同，故須以其分布函數來描述較為適切，常用的函數包括 f(y)與 d(y)。f(y)
為線能的頻率機率密度(frequency probability density)，即單位距離能量轉移為某個 y
(keV/m)之發生事件個數(event)佔全部事件個數之比率或機率；d(y)為線能的劑量機率密度
(dose probability density)，即單位距離能量轉移為某個 y (keV/m)之劑量和佔全部事件發生
所造成之總劑量之比率或機率。
比能 z 定義為單次或多次輻射能量轉移事件發生後，沉積在微觀體積中之總能量(ε)
與該微觀體積質量(m)之比，即
m
ε
z ....................................................................................................... (公式 2)
2.2 微小體積的模擬
5t
t
g
g
t
g
t
g PT
T
ΔX
ΔX
ρ
ρ
P  .................................................................................. (公式 8)
通常細胞在一大氣壓( torr760Pt  )、常溫( K310.5T ot  、 K932T og  )下之密度
1ρt  g/cm3 ，舉例來說，以一大氣壓下密度g為 0.0017 g/cm3 之組織等效氣體充入直徑
gX 為 2.5cm 之比例計數器氣體腔以度量直徑 tX 為 1m 之微觀細胞的輻射能量損失時，
將數值帶入後則得知須將充入計數器之氣體壓力控制在 17 torr。
(a)細胞或細胞核 (b)組織等效球
圖 1 藉由組織等效球模擬輻射於微觀組織中之能量沉積
三、結果與討論
本計畫已於本年期(第一年)，完成自行設計製作 3 支(含硼量不同)組織等效比例計數器
(如圖 1)，並利用核能研究所國家標準實驗室及清華大學原科中心之 Co-60 光子輻射源及核
子反應器等中子輻射源，進行微劑量計之能量校正。校正後之微劑量偵測系統始可進行醫
用直線加速器之輻射束照射，模擬偵測微小靶體積(DNA)內之線能參數分布情形。
將利用組織等效物質作為球壁的比例計數器計數器(TEPC)抽真空，並充入不同壓力的
組織等效氣體，使計數器腔內的氣體分子數與欲模擬細胞內之分子數相同，藉以模擬不同
大小的細胞。本研究所自製使用的TEPC為球型的比例計數器。圖 2為本研究所自製的TEPC
外觀，其組織等效球直徑皆為 2.5 cm，並分為含硼(50、200 ppm)2 支與不含硼(0 ppm)1 支。
此三支 TEPC 的腔壁材質為 A-150 組織等效塑膠，厚度為 2 mm，陽極為直徑 25m 的銅鈹
合金絲(98 %銅、2 %鈹)。
(a) (b)
圖 2 (a)自製 TEPC 外觀，分為含硼(50、200 ppm)2 支與不含硼(0 ppm)1 支；(b) TEPC 內部
tE
gE
gΔXtΔX
7氣體充填系統概念圖示於圖 3。本研究目前所建置之真空抽氣與氣體充填系統如圖 4 所示。
利用開啟真空幫浦與控制閥門，先將組織等效比例計數器內之殘餘不純氣體抽去，達真空
狀態，再控制閥門將組織等效氣體充入微劑量計中至預設之壓力後，將偵檢器與氣體充填
設備管線分離，即可進行照射實驗。
圖 3 真空抽氣與氣體充填系統概念圖
圖 4 本研究目前所建置之真空抽氣與氣體充填系統設備
3.3 假體製作
國際上用於放射治療的參考假體，材質主要為水，而固態假體的材質，則多以 PMMA
(polymethyl methacrylate)為主。本研究使用 PMMA 材質，製作一個直徑 16 公分、高 22 公
組織等效氣體
微劑量計
抽氣幫浦
充氣控制系統
55%
C3H8
39.6%
CO2
壓力計
控制閥(valve 1) 控制閥(valve 2)
控制閥(valve 3)
壓力控
制閥
真空
控制閥
鋼瓶控制閥
真空幫浦
氣體控
制閥
微劑
量計
9式中 R 為粒子之連續減能射程，Ei 則為入射粒子之初始能量，R(Ei)即為具 Ei 能量之
粒子其所對應的連續減能射程；c 為具 Ei 能量之粒子穿過氣體腔後之最大能量損失，
Ei-c 為粒子穿過氣體腔後剩餘的能量，R(Ei-c)即為粒子穿過氣體腔後剩餘能量所對應
之連續減能射程；d 則為每單位密度中氣體腔之微米直徑，如圖 6 所示，其中圖 6(a)表示黏
貼 241Am 校正射源於組織等效球壁上之氣孔位置，圖 6(b)則表示了依據連續減能理論所推
算出之能量與射程關係式概念圖；藉由能峰的位置對應到已知的線能，即可得到 MCA 中
頻道數對應線能的相對關係。若校正時能譜脈衝高度之頻道位置為 hc，則該能譜其餘之頻
道數 h 與所對應之線能關係式可由下式推算：
c
c
c
c
h
h
2d
3δε
h
h
l
δε
y  (公式 10)
(a) (b)
圖 6 (a)鋂-241 校正射源之設置位置示意圖，(b)連續減能理論之能量與射程關係圖
此外，以清華大學研究用反應器所產生之中子束照射，可對含硼之微劑量計進行校正。
利用硼中子捕獲反應(10B(n, α)7Li)所放出的阿伐粒子與鋰-7 粒子，在能譜中會有一分布，其
所產生之阿伐邊緣(alpha edge)亦為 TEPC 校正的方法。阿伐邊緣為阿伐粒子通過氣腔後沉
積的最多數能量所在，在模擬1 μm大小細胞的狀態下，由反應器所產生之超熱中子束測得
的阿伐邊緣所對應的線能值為386 keV/μm。直線加速器所產生之光子與電子均屬低游離能
力之輻射，因此需另使用低游離能力之輻射來做校正。本研究以銫 137(137Cs)輻射場照射，
進行低游離能力輻射之能譜校正(結果如圖 7)；由於光子屬於低游離能力之輻射，不能直接
採用阿伐射源校正所得到的相對關係，進行校正時，需調整放大器至高增益(high gain)狀
態，再量測混合場中之能譜，作為混合場之光子能譜，此方法可得到準確之光子能譜。所
得校正能譜的形狀在與 ICRU 第 36 號報告之銫 137 標準能譜進行比對找出線能和 MCA 頻
道數的轉換因數(y/ch)。
圖 7 以 137Cs 輻射場照射自製 TEPC(模擬1 μm大小之細胞)在空氣中及假體中不同深度處
量測到之能譜
鋂-241 射源(氣孔)
0.1 1 10 100 1000
0.0
0.2
0.4
0.6
0.8
1.0
yd
(y
)
y (keV/m)
in air
0 cm
4 cm
6 cm
12 cm
11
劑量平均線能皆大於 6 MV 光子束之照射結果。
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.1 1 10 100 1000
Lineal energy, y(keV/μm)
yd
(y
)
15 MV photons + PMMA
6 MV photons + PMMA
圖 9 以 TEPC 模擬 2 µm 大小之細胞組織置於 PMMA 假體中心處並以 15 MV 與 6 MV 光子
照射(SAD=100 cm，照野大小 10 × 10 cm²，量測點位於照野中心軸處)之微劑量能譜 yd(y)
分布
四、結論
本期計畫(第一年)已在清華大學原子科學技術發展中心，建構一微劑量評估專業實驗
室，建置完善之真空充氣系統及微劑量評估分析電子系統，成為國內之微劑量學應用與研
究中心。並以理論及實驗微劑量學的觀點，自製完成數支 TEPC，進行一系列校正與模擬驗
證，且利用這些自製之 TEPC 模擬不同大小(直徑 1m、2m、6m、12m 等)的細胞組
織，置於假體內不同深度處，再將假體放置在醫用直線加速器所產生之不同能量光子射束
下進行照射，評估不同能量光子射束之微劑量特性。藉由度量到之微劑量學能譜，可觀察
混合輻射場中不同 LET 的輻射之作用個數貢獻比例與劑量貢獻比例。利用在不同深度假體
中所度量之結果亦可分析散射輻射與主輻射場中各種輻射個數與劑量貢獻的分布趨勢。
本研究計畫執行完成後，將持續進行第二期(二年期)計畫，持續進行加速器之光子束及電子
束照射下之微劑量學特性分析及射束之有效相對生物效應分析，可使參與之博、碩士研究
生及大學專題生學習微劑量評估技術在放射治療的臨床劑量分析與評估有效相對生物效應
值方法，對培育相關混合輻射場劑量度量與評估之人才有助益，計畫結果預期將可提供國
內各醫院以高能直線加速器進行治療之放射腫瘤科參考，應可使國內醫界對使用直線加速
器進行放射治療所衍生的中子劑量問題的評估方法與其重要性有更深一層的認知。
參考文獻
Coutrakon, G., Cortese J., et al., 1997. Micordosimety spectrum of the Loma Linda proton beam
and relative biological effectiveness comparisons. Med. Phys. 24, 1499-1506.
Green, S., Gainey, M., and Wojnecki, C., 1998. Determination of an RBE for an Epithermal
Neutron Beam for BNCT from Microdosimetric Measurements. ISNCT8, LaJolla, California.
Hsu, F. Y., Tung, C. J. and Watt, D. E., 2003. Microdosimetric spectra of the THOR epithermal
13
計畫成果自評
本期研究為一年期計畫(後續第二期為二年期計畫，現正執行中)，以第一年的時間，建構
一微劑量評估專業實驗室，建置完善之真空充氣系統及微劑量評估分析電子系統；並自製
完成數支 TEPC，進行一系列校正與模擬驗證，且利用這些自製之 TEPC 模擬不同大小的細
胞組織，於假體內不同深度處，在醫用直線加速器所產生之不同能量光子射束下進行照射，
評估出不同能量光子射束之微劑量特性。
可供推廣之研發成果資料表
□ 可申請專利 ■可技術移轉 日期：97 年 12 月 1 日
國科會補助計畫
計畫名稱：微劑量計應用於醫用直線加速器進行放射治療之有效相
對生物效應評估(I)
計畫主持人：許芳裕
計畫編號：NSC 96-2221-E-007-140 學門領域：醫學工程(醫用電子)
技術/創作名稱 微劑量計偵測器技術
發明人/創作人 許芳裕
中文：
以國際上常使用之組織等效比例計數器作為微劑量評估儀器，評估
分析醫用直線加速器不同能量光子進行治療之微劑量線能分佈。
技術說明 英文：
Using the microdosimetry equipment: tissue equivalent proportional
counters to analyze and assess the microdosimetric lineal energy
distributions in different photon energies produced by the Linac in
radiotherapy.
可利用之產業及
可開發之產品
放射腫瘤治療之高能醫用直線加速器中子所產生不同 LET 輻射之
劑量評估。
技術特點 利用組織等效比例計數儀器進行微劑量線能分佈，評估不同 LET
輻射之劑量貢獻。
推廣及運用的價值此技術可利用單一儀器，區分出混合輻射場中不同 LET 輻射之劑
量貢獻分布，具較佳之便利性。
※ 1.每項研發成果請填寫一式二份，一份隨成果報告送繳本會，一份送 貴單位
研發成果推廣單位（如技術移轉中心）。
※ 2.本項研發成果若尚未申請專利，請勿揭露可申請專利之主要內容。
※ 3.本表若不敷使用，請自行影印使用。
目錄
壹、目的．．．．．．．．．．．．．．．．．．．．．．．．．．．．．． 1
貳、參加會議經過．．．．．．．．．．．．．．．．．．．．．．．．．． 1
一、關於中子捕獲治療國際研討會． ．．．．．． ．．． ．1
二、行程與活動． ．．．．．．．． ．．．．．．．． 1
三、會議討論重點摘要． ．．．．．．．．．．．．．．．． 2
參、與會心得與建議．．．．．．．．．．．．．．．．．．．．．．．．． 5
肆、攜回資料名稱及內容．．．．．．．．．．．．．．．．．．．．．．． 6
伍、發表論文(1)．．．．．．．．．．．．．．．．．．．．．．．．．．． 8
發表論文(2)．．．．．．．．．．．．．．．．．．．．．．．．．．． 13
211 月 4 日 (星期二) 研討會(包括口頭及壁報論文發表)
11 月 5 日 (星期三) 研討會(包括口頭及壁報論文展示)
11 月 6 日 (星期四) 研討會(包括口頭及壁報論文展示)
11 月 7 日 (星期五) 研討會(包括口頭及壁報論文展示)，大會閉幕(中午)
本人參加第 13 屆中子捕獲治療國際研討會之行程，如下表：
日 期 行 程 內 容
7 月 1-2 日
(星期六~星期日)
桃園國際機場-德國法蘭克福國際機場轉機-義大利佛羅
倫斯機場-佛羅倫斯市
7 月 3-7 日
(星期一~星期五)
佛羅倫斯市(Villa Vittoria 國際會議中心) 參加研討會並
發表論文
7 月 8-9 日
(星期六~星期日)
義大利佛羅倫斯機場-荷蘭阿姆斯特丹機場轉機-桃園國
際機場(返抵台灣)
三、會議討論重點摘要
本人於 11 月 1 日(星期六)晚上 23:45 搭乘華航班機，於 11 月 2 日清晨 6:40
到達法蘭克福機場轉機達乘中午 12:25 之班機於 13:50 底達義大利佛羅倫斯市，並
於 16:00 於 Villa Vittoria 國際會議中心完成報到程序。第 13 屆中子捕獲治療國際
研討會議於 11 月 2 日(星期日)下午 2:30 至 6:30 於佛羅倫斯市之 Palazzo dei
Congressi- Villa Vittoria 國際會議中心 1 樓之大廳辦理註冊及報到手續，報到時除
發給會議資料外，也發給歐洲 European Commission 共同研究中心(Joint Research
Centre, JRC)之相關資料供參考。下午 6:30 至 8:00 則於附近 Astoria 飯店的大廳
(Palazzo Gaddi)舉行歡迎茶會，由來自世界各地約 18 個國家之與會人員進行初步
接談與交流，為大會議程預先揭開了序幕。
大會於 11 月 3 日(星期一)上午 9:00 由會議主席義大利籍 Dr. Aris Zonta主持開
幕儀式後正式展開，其後(9:45)由美國麻州理工學院(MIT)反應器實驗室之榮譽退
休教授 Prof. Otto Harling 進行專題演講，介紹「分裂式反應器等中照射設施之硼中
子捕獲治療臨床應用(Fission Reactor Based Neutron Irradiation Facilities for Clinical
4(Neutron source)之口頭論文發表及討論；16:45 至 :18:30 則為中子源(Neutron
source)、核子工程(Neuclearengineering)、生物(Biology)硼影像(Boron imaging)及臨
床事項(Clinical matters)之壁報論文介紹。其間同時段(16:45 至 18:15)亦進行有劑量
度量技術(Dosimetry)之口頭論文發表與討論。
議程第三日(11 月 5 日，星期三)上午 8:30 至 10:30 所討論的主題為核反應器
中子源(Neutron source: Nuclear reactor)、醫學物理之劑量度量(Medical physic:
Dosimetry)、硼影像與定量(Boron imaging and quantitation)等技術之口頭論文發表
與討論；11:00 至 13:00 則為硼化學藥物研究(Chemistry and Pharmacology of boron
delivery agents)、加速器中子源 (Neutron source: Accelerators)及輻射生物學
(Radiobiology)等技術之口頭論文發表暨討論。下午時段則為開放時段，供與會者
自由安排進行討論或參訪活動。
議程第四日(11 月 6 日，星期四)上午 8:30 至 10:30 進行的是加速器中子源
(Neutron source: Accelerators)、治療計畫 (Treatment planning)及輻射生物學
(Radiobiology)等技術之口頭論文發表與討論；其後 11:00 至 13:00 則進行硼影像與
定量、中子源等技術之口頭論文發表暨討論。下午 14:30 近行了 15 分鐘左右的紀
念追思，哀悼長期從事 BNCT 研究的女士 Dr. Arlene Lennox Memorial. 隨後 15:00
至 16:30 則進行大會各委員會之改選活動。當晚 18:00 由大會安排與會者搭乘巴士
至義大利知名的葡萄酒莊園 Castello di Verrazzano 參觀並享用完餐及大會安排的現
場歌劇演唱表演。
大會於第五日(11 月 7 日，星期五)上午 8:30 至 10:30 進行的是 BNCT 之臨床
前研究(Preclinical studies)及醫學物理、中子源之劑量度量等技術之論文發表與討
論；其後 10:50 至 12:10 則進行硼影像與定量、硼化學藥物研究及輻射生物學等技
術之最後口頭論文發表暨討論。中午 12:10 開始進行此次第 13 屆中子捕獲治療國
際研討會議之閉幕儀式，並宣告二年後之第 14 屆中子捕獲治療國際研討會議將於
2010 年在南美洲的阿根廷舉行。
本人於會議結束後第二日(11 月 8 日，星期六)清晨隨即搭車至佛羅倫斯國際
機場，當承當日 7:25 分之班機飛往荷蘭阿姆斯特丹的史基浦國際機場，轉搭乘下
6BNCT 之蒙地卡羅方法計算)之合影。圖 2 則為本人於大會所安排之時段進行簡報
及壁報論文旁之留影。
圖 1 本人(右一) 於第 13 屆中子捕獲治療國際會議期間與美國哈佛大學醫學院
Stead Kiger 博士(中)及荷蘭 Petten 反應器研究中心之 Sander Nievaart 博士(左一)進
行交流討論之合影。
圖 2 本人於大會所安排之時段進行簡報(右)及壁報論文旁(左)之留影。
肆、攜回資料名稱及內容
一、大會手冊(Proceedings of 13th International Congress on Neutron Capture
Therapy“A new option against cancer”)
內容包括下列領域之論文全文：
1. Clinical matters/Biomedical application
8論文(1)
Microdosimetry Study of THOR BNCT Beam Using Tissue Equivalent
Proportional Counter
Fang-Yuh Hsua, Hsiu-Wen Hsiaob, Chuan-Jong Tungb,c, Hong-Ming Liua and Fong-In Choua
aNuclear Science Technology and Development Center, National Tsing Hua University, Taiwan
bDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University,
Taiwan
cDepartment of Medical Imaging and Radiological Science, Chang Gung University, Taiwan
Abstract
Boron neutron capture therapy (BNCT) is a cancer treatment modality using a nuclear reactor
and a boron compound drug. In Taiwan, Tsing Hua Open-pool Reactor (THOR) has been modulated
for the basic research of BNCT for years. A new BNCT beam port was built in 2004 and used to
prepare the first clinical trial in the near future. This work reports the microdosimetry study of the
THOR BNCT beam by means of the tissue equivalent proportional counter (TEPC). Two
self-fabricated TEPCs (the boron-doped versus the boron-free counter wall) were introduced. This
dual TEPC system was applied to measure the lineal energy distributions in air and water phantom
irradiated by the THOR BNCT mixed radiation field. Dose contributions from component radiations
of different linear energy transfers (LETs) were analyzed. Applying a lineal energy dependent
biological weighting function, r(y), to the total and individual lineal energy distributions, the effective
relative biological effectiveness (RBE), neutron RBE, photon RBE, and boron capture RBE (BNC
RBE) were all estimated at various depths of the water phantom. Minimum and maximum values of
the effective RBE were 1.68 and 2.93, respectively. The maximum effective RBE occurred at 2 cm
depth in the phantom. The averaged neutron RBE, photon RBE, and BNC RBE values were
3.160±0.020, 1.018±0.001, and 1.570±0.270, respectively, for the THOR BNCT beam.
Keywords: microdosimetry, RBE, TEPC, BNCT, THOR
1. Introduction
Tsing Hua open-pool reactor (THOR), a 2
MW research reactor at the National Tsing Hua
University in Taiwan, has been used in a
feasibility study for boron neutron capture
therapy (BNCT) for years. A new BNCT beam
port was built in 2004 and used to prepare the
first clinical trial in the near future. BNCT is a
binary therapy involving two components: a
boron-labeled compound that is administered to
the patient and that accumulates in tumor cells;
and irradiation by an epithermal neutron beam.
The neutron beam induces the 10B (n,) 7Li
capture reaction that emits very short-range and
high linear energy transfer (LET) particles.
These particles have a high probability of
selectively killing the boron-loaded tumor cells.
Relative biological effectiveness (RBE) and the
consequent therapeutic efficacy of BNCT are
due to the energy-range properties of the
secondary particles, the boron
micro-distribution and the morphological
properties of cells. Because of the scale of
10
0.1 1 10 100 1000
0.0
0.1
0.2
0.3
0.4
0.0
0.2
0.4
0.6
0.8
in air: 1 um
0 ppm TEPC
50 ppm TEPC
---- BNC component
yD
(y
)
(0
pp
m
T
E
P
C
)
yD
(y
)
(5
0
pp
m
T
E
P
C
)
y (keV/m))
energy and RBE, in 1990, Pihet et al.
presented the bological weighting function,
r(y), by means of the observations of early
radiation damage ( such as regenerations of
crypt cells) in rats irradiated with neutrons. r(y)
is approximatly equal to 1 for low lineal energy,
and has fluctuation for higher lineal energy.
Accroding to the measured spectra of lineal
energy, by means of the r(y) function, effective
RBE could be estimated. Effective RBE is
defined as equation 1.
 
 
( ) ( ) y d log
EffectiveRBE
( ) d log
r y d y dy yd y r y
d y dy yd y y
    
  
 
 
(eq. 1)
If the spectrum area normalized to unit dose
(eq.2), then eq.1 can be transformed to eq.3.
 d log 1yd y y   , (eq. 2)
 Effective RBE r y d logyd y y    (eq. 3)
Effective RBE can be estimate by means of
integration of the product of the measured (low
and high) lineal energy spectrum
( ( )yd y vs. log( )y ) from the boron-free TEPC
and r(y). The effective RBE is one of the
indexes of THOR beam quality.
BNCT Dose contributions from
component radiations of different linear energy
transfers (LETs) were analyzed. Applying a
lineal energy dependent biological weighting
function, r(y), to the total and individual lineal
energy distributions, the effective relative
biological effectiveness (RBE), neutron RBE,
photon RBE, and boron capture RBE (BNC
RBE) estimated. The dosimetry of BNCT is
complicated because of contribution from
multiple dose components. RBE dose for each
beam field could be calculated as equation 4,
where RBE(BNC), RBE(neutron) and
RBE(photon) are the RBE values of boron
capture, neutron and photon, respectively, and
D(BNC), D(neutron) and D(photon) represent
physical dose of boron capture, neutron and
photon, respectively. Once the effective RBE
was estimate, RBE dose can be determined by
equation 5.
RBE dose = RBE(BNC)D(BNC)
+RBE(neutron)D(neutron)
+RBE(photon)D(photon) (eq. 4)
RBE dose= effective RBE(Physical Dose)
= effective RBE[D(BNC)+
D(neutron)+D(photon)]
(eq. 5)
3. Results and discussion
Figure 3 depicts the lineal energy spectra of
the dual TEPC (0 and 50 ppm boron-doped)
system simulated 1μm cell nuclei at 6 cm apart
from THOR BNCT beam exit, measured in air.
The dash line indicates the dose contribution of
boron capture, which was obtained from the
difference of 50 ppm Boron-doped and
boron-free (0 ppm, dot line) TEPC results.
Figure 3. The lineal energy spectra of the dual
TEPC (0 and 50 ppm boron-doped) system.
Lineal energy spectrum measured by the
boron-free TEPC in 2 cm depth of the PMMA
phantom and r(y) were shown in figure 4.
Effective RBE contributed from high y
radiations (neutron and BNC) is more
important than low y radiations (photon and
electron).
12
The neutron RBE is for comparing the
beam characteristics between different BNCT
facilities. The boron concentration may vary in
different sites, therefore, boron-free lineal
spectra were chosen for the purpose of RBE
estimations. It should be noted the uncertainty
of applying the r(y) function derived from
microdosimetric measurements made for 2m
site (Loncol et al) to the measured results of 1
m site in this paper.
4. Conclusions
This work reports the microdosimetry study
of the THOR BNCT beam by means of the dual
TEPC system. Applying the lineal energy
dependent biological weighting function to the
total and individual lineal energy distributions,
the effective RBE, neutron RBE, photon RBE,
and boron capture RBE were all estimated at
various depths of the water phantom. Minimum
and maximum values of the effective RBE were
1.68 and 2.93, respectively. The maximum
effective RBE occurred at 2 cm depth in the
phantom. The averaged neutron RBE, photon
RBE, and BNC RBE values were 3.160±0.020,
1.018±0.001, and 1.570±0.270, respectively, for
the THOR BNCT beam.
References
Coutrakon, G., Cortese J., et al., 1997.
Micordosimety spectrum of the Loma Linda
proton beam and relative biological
effectiveness comparisons. Med. Phys. 24,
1499-1506.
Green, S., Gainey, M., and Wojnecki, C., 1998.
Determination of an RBE for an Epithermal
Neutron Beam for BNCT from
Microdosimetric Measurements. ISNCT8,
LaJolla, California.
Hsu, F. Y., Tung, C. J. and Watt, D. E., 2003.
Microdosimetric spectra of the THOR
epithermal neutron beam for boron neutron
capture therapy, Radiat. Prot. Dosim., 104,
No. 2, pp.121-126.
Loncol, T., Cosgrove, V., et al., 1994.
Radiobiological effectiveness of radiation
beams with broad spectra: microdosimetric
analysis using biological weighting
functions. Radiat. Prot. Dosim. 52, 347-352.
Pihet, P., Menzel, H. G., et al., 1990.
Biological weighting function for RBE
specification of neutron therapy beams.
Radiat. Prot. Dosim. 31, 431-442.
14
and a servo motor system were manufactured
to assess the depth-doses. Depth-dose
distributions for the BNCT beam for all the
above dose components were measured in the
phantom system using foil activation and dual
ion chamber techniques.
A Monte Carlo-based clinical treatment
planning code, NCTPlan (González et al., 2002,
and Hsu et al., 2002), was used to compute
dose-rate distributions for the THOR BNCT
beam within the self-made physical Snyder
phantom. Dose-rate scaling factor (DRSF) is
defined here as normalization factor derived
individually for each dose component in a
BNCT in-phantom radiation field that provides
the best agreement between measured and
computed data. If measured and computed
dose-rates completely agree, the corresponding
DRSF would be 1. Once the DRSF for each
dose component was estimated and applied in
the NCTPlan treatment planning code, the
computed dose-rate is brought into optimal
agreement with the measured dose-rate.
DRSF values for the THOR BNCT test
beam had been estimated and published in
2004 (Hsu et al., 2004). In the present work,
the comparison between the in-phantom
calculated and experimental dosimetry and the
derived DRSFs obtained with the newest
THOR BNCT beam were reported.
2. Materials and Methods
Dose components of BNCT include
thermal neutrons (thermal), fast neutron (fast),
photons (photon), and neutron-induced alpha
particles from boron-10 (B-10). The
depth-dose-rate distributions in central-axis,
for each dose component, within physical and
calculated versions of the ellipsoidal head
phantom irradiated by the newest THOR beam
were assessed by measurement and by
computation using the NCTPlan code. A
photograph of the physical self-made Snyder
phantom used for the measurements is shown
in figure 1 (left). The phantom was made of a 3
mm shell of quartz wool impregnated with
acrylic casting resin mounted on a acrylic base,
and was filled with water. A servo motor
system was manufactured to assist the
depth-dose measurements and to save the
gathering time efficiently. A set-up of the servo
motor system with the Snyder phantom is
shown in figure 1 (right).
Figure 1. The self-made ellipsoidal head
(Snyder) phantom (left), and the servo motor
system (right).
Thermal neutron fluxes were measured
using the saturated activity of bare and
cadmium-covered gold foils (American
Society for Testing and Materials, 1998).
Thermal neutron fluxes were then converted to
tissue (ICRU brain) or boron-10 dose-rates
using appropriate kerma factors (ICRU, 1992
and 2000). Fast neutron and photon dose-rates
were measured using paired ion chambers
(IC-18WP and IC-18GWP, Far West
Technology), one with graphite wall and CO2
gas, the other with A-150 plastic
tissue-equivalent (TE) wall and TE gas filling,
and both with active volumes of 0.1 ml.
Measurements were performed at 1 MW
reactor power, with the Snyder phantom
located at 10 cm apart from the physical exit
plane of the beam.
For computing the doses in NCTPlan, a 14
cm diameter source model of the newest
THOR BNCT beam was prepared from THOR
Monte Carlo simulations using MCNP code.
Corresponding dose-rates were computed
using the NCTPlan code, assuming the same
elemental material compositions as for the
measurements. The experimental and
computational irradiation conditions were
made as similar as possible in order to permit a
valid set of DRSF values to be derived. CT
scans of the physical ellipsoidal head phantom
were used as the anatomical input to NCTPlan.
DRSF values were then calculated for each
dose components. Figure 2 presents the beam
direction assignment as shown in NCTPlan.
The vertical central lines (red and blue)
16
(a) Thermal Neutron
0
2
4
6
8
10
0 2 4 6 8
depth (cm)
R
B
E
cG
y/
m
in
NCTPlan
Measurement
NCTPlan*DRSF(thermal n)
(b) Fast Neutron
0
3
6
9
12
15
0 2 4 6 8
depth (cm)
R
B
E
cG
y/
m
in
NCTPlan
Measurement
NCTPlan*DRSF(fast n)
(c) Photon
0
2
4
6
8
10
0 2 4 6 8
depth (cm)
R
B
E
cG
y/
m
in
NCTPlan
Measurement
NCTPlan*DRSF(photon)
(d) B-10 (7. 5 ppm in normal tissue)
0
2
4
6
8
10
12
14
0 2 4 6 8
depth (cm)
R
B
E
cG
y/
m
in
NCT Plan
Measurement
NCT Plan*DRSF(B-10 )
Figure 4. Depth-dose-rate distributions for all
dose components acquired by measurement,
unadjusted NCTPlan dose-rates, and adjusted
(NCTPlanDRSF) dose-rates: (a)thermal
neutron, (b)fast neutron, (c)photon, and (d) 7.5
g/g (ppm) 10B in normal tissue.
Depth-dose-rate distributions of all dose
components determined by measurement and
by NCTPlan computation, corrected with the
individually derived DRSF values, are shown
in figure 4. The DRSF values derived from the
measured and computed depth-dose-rate
distributions by least-squares criteria are as
follows: 0.64 (thermal), 1.39 (fast), 0.96
(photon), 0.65 (B-10). DRSF-adjusted
NCTPlan computed dose-rates agree well with
measured results. Average differences of each
dose component are: 2.78% for thermal
neutron, 5.67% for fast neutron, 4.11% for
photon, and 3.21% for boron-10.
Observed differences between measured
and NCTPlan computed dose-rates were found
in figure 4. The main reason for the differences
is that the source file configuration in
NCTPlan may not properly scaled due to the
physical source characteristics, such as the
actual number and position of fuel elements
used, degree of fuel burn-up, etc., may
influence the correctness of source file used
in NCTPlan. Besides, it may be due to errors in
the spatial, angular, or spectral distributions of
the neutron and photon sources and also
potential scaling errors in the analysis of
measured data having limited accuracy. In
addition, inherent to the method of mixed-field
dosimetry is the inevitably large systematic
error uncertainty associated with the derivation
of the fast neutron dose-rates. An inherent
systematic uncertainty of approximately 35%
in the determination of fast neutron dose-rates
was estimated in this study.
In comparison, the DRSF values used for
the THOR BNCT test beam were: 0.55
(thermal), 2.88 (fast), 0.53 (photon), and 0.56
(B-10). The DRSF values used for the newest
THOR BNCT beam are closer to 1. This is due
to the source normalization between calculated
and actual sources.
4. Conclusions
Comparison and analysis
between computed and measured results of
depth dose distributions were made in this
work. Monte Carlo-based BNCT treatment
